Agennix Raises $22 Million in Private Financing
Agennix, a closely held developer of protein and peptide-based drugs, announced completion of private placement financing of $22 million. "The additional capital extends our cash life well into 2007 and will enable us to capitalize on data from our ongoing Phase II trials in cancer and wound healing expected by mid-2005," said Rick Barsky, chief executive officer of Agennix. "We will also be able to initiate Phase III trials following positive data from the ongoing trials."
Yahoo News (http://biz.yahoo.com/prnews/050330/nyw027.html?.v=4)